World's Best Scientists 2026 revealed!
Keith T. Flaherty

Keith T. Flaherty

D-Index & Metrics

Medicine

D-Index
156
Citations
136827
World Ranking
897
National Ranking
512

Keith T. Flaherty publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Keith T. Flaherty sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,319 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Keith T. Flaherty D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Keith T. Flaherty sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 156 D-Index — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Keith T. Flaherty is affiliated with Harvard University in the United States and has contributed extensively to research in medicine and biochemistry, genetics, and molecular biology. Their work spans several subfields, with a strong focus on oncology, molecular biology, cancer research, pulmonary and respiratory medicine, and immunology.

Their main research topics include:

  • Melanoma and MAPK Pathways
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • CAR-T cell therapy research
  • Cutaneous Melanoma Detection and Management
  • Colorectal Cancer Treatments and Studies
  • Immunotherapy and Immune Responses

Keith T. Flaherty has published extensively in high-impact scientific journals. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Cancer Research
  • bioRxiv (Cold Spring Harbor Laboratory)
  • JCO Precision Oncology

Some of their recent papers are:

  • "SARS-CoV-2 viral load is associated with increased disease severity and mortality" (2020, Nature Communications)
  • "Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity" (2020, Science)
  • "Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)" (2020, Journal of Clinical Oncology)
  • "Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H" (2020, Journal of Clinical Oncology)
  • "The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design" (2020, JNCI Journal of the National Cancer Institute)

Keith T. Flaherty has collaborated with several frequent co-authors including:

  • Genevieve M. Boland
  • Lyndsay N. Harris
  • Lisa M. McShane
  • Ryan J. Sullivan
  • Stanley R. Hamilton

Best Publications

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Final Version of 2009 AJCC Melanoma Staging and Classification

    Charles M. Balch;Jeffrey E. Gershenwald;Seng Jaw Soong;John F. Thompson

  • Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

    Itay Tirosh;Benjamin Izar;Benjamin Izar;Sanjay M. Prakadan;Marc H. Wadsworth

  • Inhibition of mutated, activated BRAF in metastatic melanoma.

    Keith T. Flaherty;Igor Puzanov;Kevin B. Kim;Antoni Ribas

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • Genomic Classification of Cutaneous Melanoma

    Rehan Akbani;Kadir C. Akdemir;B. Arman Aksoy;Monique Albert

  • Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski

  • Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

  • Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

    Keith T. Flaherty;Caroline Robert;Peter Hersey;Paul Nathan

  • Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

    K T Flaherty;C Robert;P Hersey;P Nathan;P Nathan

  • Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

    Jeffrey E. Gershenwald;Richard A. Scolyer;Kenneth R. Hess;Vernon K. Sondak

  • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma

    Gideon Bollag;Peter Hirth;James Tsai;Jiazhong Zhang

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

    Ravid Straussman;Teppei Morikawa;Kevin Shee;Michal Barzily-Rokni

  • Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.

    Leore T. Geller;Michal Barzily-Rokni;Tal Danino;Oliver H. Jonas;Oliver H. Jonas

  • COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

    Cory M Johannessen;Jesse S. Boehm;So Young Kim;Sapana R. Thomas;Sapana R. Thomas

  • RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

    Poulikos I. Poulikakos;Yogindra Persaud;Manickam Janakiraman;Xiangju Kong

  • Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

    Moshe Sade-Feldman;Moshe Sade-Feldman;Keren Yizhak;Stacey L. Bjorgaard;Stacey L. Bjorgaard;John P. Ray

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

  • Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

    I. Tirosh;B. Izar;D. Treacy;J. J. Trombetta

Frequent Co-Authors

Ryan J. Sullivan
Ryan J. Sullivan Harvard University
Dennie T. Frederick
Dennie T. Frederick Broad Institute
Georgina V. Long
Georgina V. Long University of Sydney
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Jennifer A. Wargo
Jennifer A. Wargo The University of Texas MD Anderson Cancer Center
Reinhard Dummer
Reinhard Dummer University of Zurich
Claus Garbe
Claus Garbe University of Tübingen
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Caroline Robert
Caroline Robert University of Paris-Saclay

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in medicine but prefer flexible study options? There are several accredited online degrees that can launch your career in healthcare without the need for traditional, on-campus programs.

Many students are choosing a health information technology online degree to enter the growing field of medical records management. This pathway offers job stability and the opportunity to work in both clinical and non-clinical settings.

Those looking for fast entry into the workforce may consider a medical billing and coding certification online. These programs are designed to be completed in less time and train students in essential skills for administrative roles in healthcare.

Aspiring nurses can save on tuition with affordable nursing programs online or pursue advanced practice through the cheapest online fnp program. Both tracks offer flexibility for working professionals and help address the national demand for skilled nurses.

Each online pathway provides an accessible, affordable alternative to traditional degrees, opening more opportunities in America’s dynamic healthcare sector.

Best Scientists Citing Keith T. Flaherty

Trending Scientists

Recently Published Articles